<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50427">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02101229</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01657-38</org_study_id>
    <nct_id>NCT02101229</nct_id>
  </id_info>
  <brief_title>Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital</brief_title>
  <acronym>WP6 1</acronym>
  <official_title>Diabeloop WP6. 1 : Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether the DIABELOOP algorithm provides better glycemic control than the usual
      algorithm of T1D patients on pump therapy:

        -  at meals, with CHO roughly assessed by the patient.

        -  during and after physical activity sessions qualified as moderate by the patient.

      Primary endpoint : time within the glycemic reference range. The study will be conduct with
      15 patients at the following investigation centers : Corbeil Hospital, CHU of Grenoble, and
      CHU of Montpellier.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 15 patients will have 2 visits during 24 hours (day and night), once with their usual
      algorithm and once with the Diabeloop system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Time spent in blood glucose range [70-180 mg/dl]</measure>
    <time_frame>up to 24 hours after each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>comparing the time spent in [70-180 mg/dl] with usual algorithm vs Diabeloop algorithm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time spent Blood Glucose range [80-140 mg/dl]</measure>
    <time_frame>24 hours after each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparing the time spent in range [80-140 mg/dl] with usual algorithm vs Diabeloop algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time spent below 70 mg/dl and above 180 mg/dl</measure>
    <time_frame>up to 24 hours after each treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>unsual treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient will have his usual treatment in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The Diabeloop algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin, Asp(B28)-</intervention_name>
    <description>the insulin dose is calculated by the &quot;Diabeloop&quot; algorithm and then administered to the patient</description>
    <arm_group_label>The Diabeloop algorithm</arm_group_label>
    <other_name>NovoRapid insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient type 1 diabetic for at least one year

          -  Patient treated by external insulin pump for at least 6 months

          -  Patients with HbA1c &lt;9%

          -  Patient affiliated with Social Security.

          -  Patient able to perform two tests of physical activity of 30 minutes (one event in
             each treatment period);

          -  aged at least 18 years Patient;

          -  Patient who signed consent

        Exclusion Criteria:

          -  All serious disease that could interfere with the study

          -  BMI &gt; 30 kg/m2

          -  insulin requirement &gt; 2 U/kg/day

          -  Patient benefiting from a measure of legal protection;

          -  Pregnant or likely to be women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia FRANC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed DAOUDI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Yves BENHAMOU, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandrine LABLANCHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Grenoble</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric RENARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne FARRET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume CHARPENTIER, MD</last_name>
    <phone>+33164968654</phone>
    <email>pers@ceritd.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier du Sud Francillien</name>
      <address>
        <city>Evry</city>
        <zip>91058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycemic control algorithm</keyword>
  <keyword>closed loop</keyword>
  <keyword>artificial pancreas</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
